Modeling gender effects on electrical activity of single ventricular myocytes

Computers in Biology and Medicine

Volumn 43, Issue 8, 2013, Pages 1063-1072

  Cieniawa, Jerzy ^a   Baszak, Jacek ^a   Olchowik, Grazyna ^a   Widomska, Justyna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Action potential; Arrhythmias; Heart; Sex

Indexed keywords

ACTION POTENTIALS; ARRHYTHMIAS; EARLY AFTER DEPOLARIZATION; ELECTRICAL ACTIVITIES; GENDER-RELATED DIFFERENCES; LEFT VENTRICULAR MYOCYTES; SEX; TRANSIENT OUTWARD POTASSIUM CURRENT;

CALCIUM; DOMES; ELECTROPHYSIOLOGY; HEART; MATHEMATICAL MODELS; POTASSIUM; SODIUM;

ELECTRIC RECTIFIERS;

CALCIUM CHANNEL L TYPE;

ANIMAL EXPERIMENT; ARTICLE; BRUGADA SYNDROME; DOG; FEMALE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART RIGHT VENTRICLE; LONG QT SYNDROME; MALE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; REPOLARIZATION; SEX DIFFERENCE; SODIUM CURRENT;

ACTION POTENTIALS; ALGORITHMS; CALCIUM; COMPUTER SIMULATION; FEMALE; HEART; HEART VENTRICLES; HUMANS; MALE; MODELS, CARDIOVASCULAR; MYOCYTES, CARDIAC; PERICARDIUM; POTASSIUM; SEX FACTORS; SODIUM;

EID: 84879786587     PISSN: 00104825     EISSN: 18790534     Source Type: Journal    
DOI: 10.1016/j.compbiomed.2013.05.002     Document Type: Article

References (92)

1. Ebert S.N., Liu X.K., Woosley R.L. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J. Womens Health 1998, 7:547-557.
2. Hreiche R., Morissette P., Turgeon J. Drug-induced long QT syndrome in women: review of current evidence and remaining gaps. Gend. Med. 2008, 5:124-135.
3. Locati E.H., Zareba W., Moss A.J., Schwartz P.J., Vincent G.M., Lehmann M.H., Towbin J.A., Priori S.G., Napolitano C., Robinson J.L., Andrews M., Timothy K., Hall W.J. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation 1998, 97:2237-2244.
4. Makkar R.R., Fromm B.S., Steinman R.T., Meissner M.D., Lehmann M.H. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. J. Am. Med. Assoc. 1993, 270:2590-2597.
5. Sims C., Reisenweber S., Viswanathan P.C., Choi B.R., Walker W.H., Salama G. Sex, age, and regional differences in L-type calcium current are important determinants of arrhythmia phenotype in rabbit hearts with drug-induced long QT type 2. Circ. Res. 2008, 102:e86-e100.
6. Eckardt L. Gender differences in Brugada syndrome. J. Cardiovasc. Electrophysiol. 2007, 18:422-424.
7. Matsuo K., Akahoshi M., Nakashima E., Suyama A., Seto S., Hayano M., Yano K. The prevalence, incidence and prognostic value of the Brugada-type electrocardiogram: a population-based study of four decades. J. Am. Coll. Cardiol. 2001, 38:765-770.
8. Shimizu W. Gender difference and drug challenge in Brugada syndrome. J. Cardiovasc. Electrophysiol. 2004, 15:70-71.
9. Liu X., Katchman A., Drici M., Ebert S., Ducic I., Morad M., Woosley R. Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J. Pharmacol. Exp. Ther. 1998, 285:672-679.
10. Pham T., Robinson R., Danilo P.J., Rosen M. Effects of gonadal steroids on gender-related differences in transmural dispersion of L-type calcium current. Cardiovasc. Res. 2002, 53:752-762.
11. Na in female dog ventricle as a mechanism for gender-specific incidence of cardiac arrhythmias. Cardiovasc. Res. 2009, 81:82-89.
12. Di Diego J., Cordeiro J., Goodrow R., Fish J., Zygmunt A., Pérez G., Scornik F., Antzelevitch C. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 2002, 106:2004-2011.
13. Xiao L., Zhang L., Han W., Wang Z., Nattel S. Sex-based transmural differences in cardiac repolarization and ionic-current properties in canine left ventricles. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H570-H580.
14. Brouillette J., Rivard K., Lizotte E., Fiset C. Sex and strain differences in adult mouse cardiac repolarization: importance of androgens. Cardiovasc. Res. 2005, 65:148-157.
15. + currents in diabetic rat cardiac myocytes. J. Physiol. 2003, 550:401-412.
16. 2+ cycling in intact rat heart: a comparison of sex differences. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H1895-H1904.
17. James A., Arberry L., Hancox J. Gender-related differences in ventricular myocyte repolarization in the guinea pig. Basic Res. Cardiol. 2004, 99:183-192.
18. Verkerk A., Wilders R., de Geringel W., Tan H. Cellular basis of sex disparities in human cardiac electrophysiology. Acta Physiol. (Oxf) 2006, 187:459-477.
19. Verkerk A., Wilders R., Tan H. Gender disparities in torsade de pointes ventricular tachycardia. Basic Res. Heart J. 2007, 15:405-411.
20. Verkerk A., Wilders R., Veldkamp M., de Geringel W., Kirkels J., Tan H. Gender disparities in cardiac cellular electrophysiology and arrhythmia susceptibility in human failing ventricular myocytes. Int. Heart J. 2005, 46:1105-1118.
21. Priebe L., Beuckelmann D. Simulation study of cellular electric properties in heart failure. Circ. Res. 1998, 82:1206-1223.
22. ten Tusscher K., Noble D., Noble P., Panfilov A. A model for human ventricular tissue. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H1573-H1589.
23. Wu Y., Anderson M. Reduced repolarization reserve in ventricular myocytes from female mice. Cardiovasc. Res. 2002, 53:763-769.
24. 1 subunit. J. Physiol. Sci. 2009, 59:217-225.
25. Hund T., Rudy Y. Rate dependence and regulation of action potential and calcium transient in a canine cardiac ventricular cell model. Circulation 2004, 110:3168-3174.
26. Näbauer M., Beuckelmann D.J., Uberfuhr P., Steinbeck G. Regional differences in current density and rate-dependent properties of the transient outward current in subepicardial and subendocardial myocytes of human left ventricle. Circulation 1996, 93:168-177.
27. Wettwer E., Amos G.J., Posival H., Ravens U. Transient outward current in human ventricular myocytes of subepicardial and subendocardial origin. Circ. Res. 1994, 75:473-482.
28. Grandi E., Pasqualini F.S., Bers D.M. A novel computational model of the human ventricular action potential and Ca transient. J. Mol. Cell. Cardiol. 2010, 48:112-121.
29. Krogh-Madsen T., Schaffer P., Skriver A.D., Taylor L.K., Pelzmann B., Koidl B., Guevara M.R. An ionic model for rhythmic activity in small clusters of embryonic chick ventricular cells. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H398-H413.
30. Maltsev V.A., Sabbah H.N., Undrovinas A.I. Late sodium current is a novel target for amiodarone: studies in failing human myocardium. J. Mol. Cell. Cardiol. 2001, 33:923-932.
31. Maltsev V.A., Undrovinas A. Late sodium current in failing heart: friend or foe?. Prog. Biophys. Mol. Biol. 2008, 96:421-451.
32. Xi Y., Wu G., Yang L., Han K., Du Y., Wang T., Lei X., Bai X., Ma A. Increased late sodium currents are related to transcription of neuronal isoforms in a pressure-overload model. Eur. J. Heart Fail. 2009, 11:749-757.
33. Wang H., Cohen I. Calcium channel heterogeneity in canine left ventricular myocytes. J. Physiol. 2003, 547:825-833.
34. Veldkamp M., Verkerk A., van Ginneken A., Baartscheer A., Schumacher C., de Jonge N., de Bakker J., Opthof T. Norepinephrine induces action potential prolongation and early afterdepolarizations in ventricular myocytes isolated from human end-stage failing hearts. Eur. Heart J. 2001, 22:955-963.
35. Weiss J.N., Garfinkel A., Karagueuzian H.S., Chen P.S., Qu Z. Early afterdepolarizations and cardiac arrhythmias. Heart Rhythm 2010, 7:1891-1899.
36. 2+ exchange: evidence for differential expression in normal and failing hearts. Circ. Res. 2005, 97:207-209.
37. NaCa contributes to electrical heterogeneity within the canine ventricle. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H1671-H1678.
38. Antzelevitch C. Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H2024-H2038.
39. Ks are larger in right than left canine ventricular midmyocardium. Circulation 1999, 99:206-210.
40. Tan H.L., Bezzina C.R., Smits J.P., Verkerk A.O., Wilde A.A. Genetic control of sodium channel function. Cardiovasc. Res. 2003, 57:961-973.
41. Dumaine R., Towbin J.A., Brugada P., Vatta M., Nesterenko D.V., Nesterenko V.V., Brugada J., Brugada R., Antzelevitch C. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ. Res. 1999, 85:803-809.
42. Bébarová M., O'Hara T., Geelen J., Jongbloed R., Timmermans C., Arens Y., Rodriguez L., Rudy Y., Volders P. Subepicardial phase 0 block and discontinuous transmural conduction underlie right precordial ST-segment elevation by a SCN5A loss-of-function mutation. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H48-H58.
43. Sakmann B.F., Spindler A.J., Bryant S.M., Linz K.W., Noble D. Distribution of a persistent sodium current across the ventricular wall in guinea pigs. Circ. Res. 2000, 87:910-914.
44. Zygmunt A.C., Eddlestone G.T., Thomas G.P., Nesterenko V.V., Antzelevitch C. Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am. J. Physiol. Heart Circ. Physiol. 2001, 281:H689-H697.
45. Shimizu W., Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of β-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 1998, 98:2314-2322.
46. Shimizu W., Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 1997, 96:2038-2047.
47. Bennett P.B., Yazawa K., Makita N., George A.L. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995, 376:683-685.
48. Rivolta I., Abriel H., Tateyama M., Liu H., Memmi M., Vardas P., Napolitano C., Priori S.G., Kass R.S. Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. J. Biol. Chem. 2001, 276:30623-30630.
49. + channels expressed in mammalian cells. Am. J. Physiol. 1998, 274:H1643-H1654.
50. Naccarelli G.V., Lee K.S., Gibson J.K., VanderLugt J. Electrophysiology and pharmacology of ibutilide. Am. J. Cardiol. 1996, 78:12-16.
51. Kr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation 1995, 91:1799-1806.
52. Rodriguez I., Kilborn M.J., Liu X.K., Pezzullo J.C., Woosley R.L. Drug-induced QT prolongation in women during the menstrual cycle. J. Am. Med. Assoc. 2001, 285:1322-1326.
53. Gowda R.M., Khan I.A., Punukollu G., Vasavada B.C., Sacchi T.J., Wilbur S.L. Female preponderance in ibutilide-induced torsade de pointes. Int. J. Cardiol. 2004, 95:219-222.
54. v1.5 channels. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H288-H299.
55. Antzelevitch C., Belardinelli L. The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis. J. Cardiovasc. Electrophysiol. 2006, 17(Suppl. 1):S79-S85.
56. 2+ current. Circ. Res. 1989, 64:977-990.
57. January C.T., Moscucci A. Cellular mechanisms of early afterdepolarizations. Ann. NY Acad. Sci. 1992, 644:23-32.
58. Roden D.M. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 2004, 350:1013-1022.
59. Viswanathan P., Rudy Y. Pause induced early afterdepolarizations in the long QT syndrome: a simulation study. Cardiovasc. Res. 1999, 42:530-542.
60. Luo C., Rudy Y. A dynamic model of the cardiac ventricular action potential. II. Afterdepolarizations, triggered activity, and potentiation. Circ. Res. 1994, 74:1097-1113.
61. Cheng J. Evidences of the gender-related differences in cardiac repolarization and the underlying mechanisms in different animal species and human. Fundam. Clin. Pharmacol 2006, 20:1-8.
62. Coker S.J. Drugs for men and women-how important is gender as a risk factor for TdP?. Pharmacol. Ther. 2008, 119:186-194.
63. James A.F., Choisy S.C., Hancox J.C. Recent advances in understanding sex differences in cardiac repolarization. Prog. Biophys. Mol. Biol. 2007, 94:265-319.
64. Jonsson M.K., Vos M.A., Duker G., Demolombe S., van Veen T.A. Gender disparity in cardiac electrophysiology: implications for cardiac safety pharmacology. Pharmacol. Ther. 2010, 127:9-18.
65. to) in shaping canine ventricular action potential--a dynamic clamp study. J. Physiol. 2005, 564:411-419.
66. to1 in shaping action potential morphology and duration. Circ. Res. 2000, 87:1026-1033.
67. Miyoshi S., Mitamura H., Fujikura K., Fukuda Y., Tanimoto K., Hagiwara Y., Ita M., Ogawa S. A mathematical model of phase 2 reentry: role of L-type Ca current. Am. J. Physiol. Heart Circ. Physiol 2003, 284:H1285-H1294.
68. Moss A.J., Windle J.R., Hall W.J., Zareba W., Robinson J.L., McNitt S., Severski P., Rosero S., Daubert J.P., Qi M., Cieciorka M., Manalan A.S. Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (δKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann. Noninvasive Electrocardiol. 2005, 10:59-66.
69. Makita N., Behr E., Shimizu W., Horie M., Sunami A., Crotti L., Schulze-Bahr E., Fukuhara S., Mochizuki N., Makiyama T., Itoh H., Christiansen M., McKeown P., Miyamoto K., Kamakura S., Tsutsui H., Schwartz P.J., George A.L., Roden D.M. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J. Clin. Invest. 2008, 118:2219-2229.
70. Priori S.G., Napolitano C., Schwartz P.J., Bloise R., Crotti L., Ronchetti E. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation 2000, 102:945-947.
71. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J. Cardiovasc. Electrophysiol. 2001, 12:268-272.
72. Antzelevitch C., Shimizu W., Yan G.X., Sicouri S., Weissenburger J., Nesterenko V.V., Burashnikov A., Di Diego J., Saffitz J., Thomas G.P. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J. Cardiovasc. Electrophysiol. 1999, 10:1124-1152.
73. Roden D.M., Lazzara R., Rosen M., Schwartz P.J., Towbin J., Vincent G.M. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 1996, 94:1996-2012.
74. Paulussen A.D.C., Aerssens J. Risk factors for drug-induced long-QT syndrome. Neth. Heart J. 2005, 13:47-56.
75. Kannankeril P.J., Roden D.M. Drug-induced long QT and torsade de pointes: recent advances. Curr. Opin. Cardiol. 2007, 22:39-43.
76. Bednar M.M., Harrigan E.P., Ruskin J.N. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am. J. Cardiol. 2002, 89:1316-1319.
77. Drici M.D., Knollmann B.C., Wang W.X., Woosley R.L. Cardiac actions of erythromycin: influence of female sex. J. Am. Med. Assoc. 1998, 280:1774-1776.
78. Waldo A.L., Camm A.J., deRuyter H., Friedman P.L., MacNeil D.J., Pauls J.F., Pitt B., Pratt C.M., Schwartz P.J., Veltri E.P. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction, The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996, 348:7-12.
79. Lehmann M.H., Hardy S., Archibald D., quart B., MacNeil D.J. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996, 94:2535-2541.
80. Liu X.K., Wang W., Ebert S.N., Franz M.R., Katchman A., Woosley R.L. Female gender is a risk factor for torsades de pointes in an in vitro animal model. J. Cardiovasc. Pharmacol. 1999, 34:287-294.
81. K-blocking drugs. Circulation 2001, 103:2207-2212.
82. Ruan Y.F., Liu N., Zhou Q., Li Y., Wang L. Experimental study on the mechanism of sex difference in the risk of torsade de pointes. Chin. Med. J. (Engl) 2004, 117:538-541.
83. Zareba W., Moss A.J., Locati E.H., Lehmann M.H., Peterson D.R., Hall W.J., Schwartz P.J., Vincent G.M., Priori S.G., Benhorin J., Towbin J.A., Robinson J.L., Andrews M.L., Napolitano C., Timothy K., Zhang L., Medina A., Registry I.L.Q.S. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J. Am. Coll. Cardiol. 2003, 42:103-109.
84. Shimoni Y., Emmett T., Schmidt R., Nygren A., Kargacin G. Sex-dependent impairment of cardiac action potential conduction in type 1 diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H1442-H1450.
85. Pham T.V., Rosen M.R. Sex, hormones, and repolarization. Cardiovasc. Res. 2002, 53:740-751.
86. Yang P.C., Clancy C.E. Effects of sex hormones on cardiac repolarization. J. Cardiovasc. Pharmacol. 2010, 56:123-129.
87. Opthof T., Coronel R., Janse M.J. Is there a significant transmural gradient in repolarization time in the intact heart?: repolarization gradients in the intact heart. Circ. Arrhythm. Electrophysiol. 2009, 2:89-96.
88. Anyukhovsky E.P., Sosunov E.A., Gainullin R.Z., Rosen M.R. The controversial M cell. J. Cardiovasc. Electrophysiol. 1999, 10:244-260.
89. Coronel R., Casini S., Koopmann T., Wilms-Schopman F., Verkerk A., de Groot J., Bhuiyan Z., Bezzina C., Veldkamp M., Linnenbank A., van der Wal A., Tan H., Brugada P., Wilde A., de Bakker J. Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study. Circulation 2005, 112:2769-2777.
90. Drici M.D., Clément N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf. 2001, 24:575-585.
91. Fink M., Noble D. Pharmacodynamic effects in the cardiovascular system: the modeller's view. Basic Clin. Pharmacol. Toxicol. 2010, 106:243-249.
92. Kohl P., Noble D. Systems biology and the virtual physiological human. Mol. Syst. Biol. 2009, 5:292.